Abstract| Volume 32, ISSUE 2, P199, April 2019

13. Prevention of Recurrent Mucinous Borderline Ovarian Tumor with Aromatase Inhibitor

      Aromatase inhibitors (AIs) have been utilized for a number of estrogen-modulated conditions, including hormone-sensitive breast cancer, endometriosis and ovulation induction. Some borderline ovarian tumors (BOT) are estrogen-receptor positive, and case reports suggest the use of AIs in the prevention of recurrent serous BOT. We present a case of progression from mucinous cystadenoma to mucinous BOT after two prior cystectomies in whom an AI was used and the patient is now 2 years without recurrent disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect